---
company: Electromed, Inc.
ticker: ELMD
form: 8-K
filed: 2026-08-25
accession: 0001437749-26-028915
source: https://www.sec.gov/Archives/edgar/data/1488917/000143774926028915/
---

# Electromed (ELMD) earnings release, August 25, 2026

Electromed, Inc. (ELMD) · Form 8-K, Item 2.02 · Filed 2026-08-25 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1488917/000143774926028915/)

Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results

Strong homecare revenue growth and expanded operating leverage drive record operating income in Fiscal 2026

NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2026") and full year ended June 30, 2026 ("FY 2026").

Q4 FY 2026 Company Highlights

FY 2026 Company Highlights

“Fiscal 2026 was another exceptional year for Electromed, as the company generated record revenues and profits. The fourth fiscal quarter marked our 15th consecutive quarter of year-over-year revenue and profit growth. Also, our operating margin increased more than 370 basis points over FY 2025, which demonstrates our continued success in driving operational leverage. Our strong financial performance, combined with strategic investments in our sales force, systems, and bronchiectasis market development initiatives, positions us to capitalize on the opportunity to serve the approximately 800,000 diagnosed bronchiectasis patients who could benefit from our SmartVest® therapy. Our robust balance sheet with $

20.5 million in cash, and recognition as one of Minnesota’s fastest-growing public companies has Electromed well-positioned for durable, long-term growth and value creation for our investors.”

Q4

FY 2026 Results

All amounts below are for the three months ended

June 30, 2026, and compare to the three months ended

June 30, 2025.

Net revenues grew

11.6% to $

19.4 million from $

17.4 million.

Revenue in our direct homecare business increased

15.2% to $

17.7 million from $

15.4 million. The increase in revenue was primarily due to an increase in direct sales representatives, increased sales representative productivity, and higher net revenues per approval.

Gross profit increased to $

15.3 million or

78.7% of net revenues from $

13.6 million or

78.3% of net revenues. The increase in gross profit and gross margin was primarily due to increased revenue and higher net revenue per device.

Selling, general and administrative (“SG&A”) expenses were $

11.1 million, representing an increase of $

0.8 million or

8.3%. The increase in the current period was primarily due to the increased salaries and incentive compensation related to the higher average number of personnel in the sales, sales support, marketing, and reimbursement teams to process higher patient referrals.

Operating income was $

3.8 million or

19.7% of net revenues, compared to $

3.0 million, or

17.5% of net revenues. This increase in operating income was primarily due to increases in revenue and gross profit.

Net income increased by

54.3% to $

3.4 million, or $

0.39 per diluted share, compared to $

2.2 million, or $

0.25 per diluted share.

FY 2026 Summary

All amounts below are for the year ended June 30, 2026 ("fiscal 2026") and compare to the fiscal year ended June 30, 2025 ("fiscal 2025").

Net revenues for fiscal 2026 grew by

15.3% to a record $

73.8 million, from $

64.0 million in fiscal 2025.

Revenue in our direct homecare market increased year-over-year by

16.3% to $

66.6 million, from $

57.3 million. The increase in revenue was due to an increase in direct sales representatives, increased sales representative productivity, and higher net revenues per approval. For the year ended June 30, 2026, we averaged 58 homecare field sales representatives. The homecare revenue per weighted average direct sales representative was $1,145,000, exceeding Electromed's target range for the year of $1,000,000 to $1,100,000.

Revenue in our non-homecare business grew to $

7.2 million in fiscal 2026, an increase of $

0.5 million, or

6.7%, from $

6.7 million in fiscal 2025. The increase was primarily due to increased distributor and hospital revenue.

Gross profit increased to $

57.9 million, or

78.5% of net revenues in fiscal 2026, from $

50.0 million, or

78.1% of net revenues, in fiscal 2025. The increase in gross profit and gross margin was primarily due to increased revenue and higher net revenue per device.

Selling, general and administrative (“SG&A”) expenses were $

42.7 million in fiscal 2026, representing an increase of $

3.4 million or

8.7% from $

39.3 million in fiscal 2025. The increase was primarily due to increased salaries and incentive compensation related to the higher average number of personnel in the sales, sales support, marketing, and reimbursement teams to process more patient referrals.

Operating income was $

13.9 million or

18.8% of net revenues in fiscal 2026, compared to $

9.7 million, or

15.1% of net revenues in fiscal 2025. This increase in operating income was primarily due to increases in net revenues and gross profit.

Net income for fiscal 2026 was $

11.3 million, or $

1.30 per diluted share, compared to $

7.5 million, or $

0.85 per diluted share in fiscal 2025.

As of

June 30, 2026, Electromed had $

20.5 million in cash, $

29.8 million in accounts receivable and no debt, achieving working capital of $

45.1 million and total shareholders’ equity of $

54.0 million. The cash balance reflects an increase of $

5.2 million for the twelve months ended

June 30, 2026, compared to a decrease in cash of $0.8 million in the twelve months ended June 30, 2025. The increase in cash for the twelve months ended

June 30, 2026, was driven primarily by positive operating cash flow of $9.7 million, partially offset by share repurchases of $3.9 million of Electromed common stock.

Conference Call and Webcast Information

The conference call with members of Electromed management will be held at 5:00 p.m. Eastern Time on Tuesday, August 25, 2026.... (truncated)(877) 407-3982 (Domestic) or (201) 493-6780 (International).

The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1770216&tp_key=c0342b57c3

For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 13761827. Additionally, an online replay will be available for at least one year in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Cautionary Statements

Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “continue,” “expect,” “may,” “plan,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown, associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases, inflationary trends in electronic components, and uncertainty related to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; rising energy costs and geopolitical conflict; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Brad Nagel, Chief Financial Officer

(952) 758-9299 investorrelations@electromed.com

Mike Cavanaugh, Investor Relations

ICR Healthcare

(617) 877-9641 mike.cavanaugh@icrhealthcare.com

Source: Electromed, Inc.

Electromed, Inc.

Condensed Balance Sheets

Electromed, Inc.

Condensed Statements of Operations

Electromed, Inc.

Condensed Statements of Cash Flows

## Financial statements

### Income Statement (Three Months Ended — Condensed Statements of Operations)

| | Three Months Ended – June 30, – 2026 – (Unaudited) | Three Months Ended – June 30, – 2025 – (Unaudited) | Year Ended – June 30, – 2026 | Year Ended – June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net revenues | 19,417,000 | 17,393,000 | 73,776,000 | 64,000,000 |
| Cost of revenues | 4,133,000 | 3,769,000 | 15,833,000 | 14,029,000 |
| Gross profit | 15,284,000 | 13,624,000 | 57,943,000 | 49,971,000 |
| Operating expenses | Selling, general and administrative | 11,131,000 | 10,282,000 | 42,748,000 | 39,315,000 |
| Operating expenses | Research and development | 328,000 | 302,000 | 1,314,000 | 996,000 |
| Operating expenses | Total operating expenses | 11,459,000 | 10,584,000 | 44,062,000 | 40,311,000 |
| Operating expenses | Operating income | 3,825,000 | 3,040,000 | 13,881,000 | 9,660,000 |
| Operating expenses | Interest income, net | 136,000 | 135,000 | 479,000 | 624,000 |
| Operating expenses | Net income before income taxes | 3,961,000 | 3,175,000 | 14,360,000 | 10,284,000 |
| Operating expenses | Income tax expense | 560,000 | 971,000 | 3,059,000 | 2,747,000 |
| Operating expenses | Net income | 3,401,000 | 2,204,000 | 11,301,000 | 7,537,000 |
| Income per share: | Basic | 0.41 | 0.26 | 1.37 | 0.89 |
| Income per share: | Diluted | 0.39 | 0.25 | 1.3 | 0.85 |
| Weighted-average common shares outstanding: | Basic | 8,258,440 | 8,334,821 | 8,266,071 | 8,454,100 |
| Weighted-average common shares outstanding: | Diluted | 8,734,188 | 8,718,900 | 8,688,563 | 8,914,421 |

### Balance Sheet (As of June 30, — Condensed Balance Sheets)

| | As of June 30, – 2026 | As of June 30, – 2025 |
|---|---:|---:|
| Current Assets | Cash and cash equivalents | 20,450,000 | 15,287,000 |
| Current Assets | Accounts receivable (net of allowances for credit losses of $45,000) | 29,805,000 | 24,660,000 |
| Current Assets | Contract assets | 1,094,000 | 1,036,000 |
| Current Assets | Inventories | 3,681,000 | 3,299,000 |
| Current Assets | Prepaid expenses and other current assets | 1,170,000 | 392,000 |
| Current Assets | Income tax receivable | 1,168,000 | 408,000 |
| Current Assets | Total current assets | 57,368,000 | 45,082,000 |
| Current Assets | Property and equipment, net | 5,214,000 | 4,714,000 |
| Current Assets | Finite-life intangible assets, net | 379,000 | 371,000 |
| Current Assets | Other assets | 1,270,000 | 1,173,000 |
| Current Assets | Deferred income taxes | 2,036,000 | 2,462,000 |
| Current Assets | Total assets | 66,267,000 | 53,802,000 |
| Current Liabilities | Accounts payable | 2,643,000 | 2,667,000 |
| Current Liabilities | Accrued compensation | 6,071,000 | 5,079,000 |
| Current Liabilities | Warranty reserve | 1,899,000 | 1,645,000 |
| Current Liabilities | Other accrued liabilities | 1,609,000 | 1,077,000 |
| Current Liabilities | Total current liabilities | 12,222,000 | 10,468,000 |
| Current Liabilities | Other long-term liabilities | 66,000 | 125,000 |
| Current Liabilities | Total liabilities | 12,288,000 | 10,593,000 |
| Shareholders’ Equity | Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,366,163 and 8,349,176 shares issued and outstanding, as of June 30, 2026, and June 30, 2025, respectively | 84,000 | 83,000 |
| Shareholders’ Equity | Additional paid-in capital | 25,331,000 | 21,941,000 |
| Shareholders’ Equity | Retained earnings | 28,564,000 | 21,185,000 |
| Shareholders’ Equity | Total shareholders’ equity | 53,979,000 | 43,209,000 |
| Shareholders’ Equity | Total liabilities and shareholders’ equity | 66,267,000 | 53,802,000 |

### Cash Flow (Years Ended June 30, — Condensed Statements of Cash Flows)

| | Years Ended June 30, – 2026 | Years Ended June 30, – 2025 |
|---|---:|---:|
| Cash Flows from Operating Activities | Net income | 11,301,000 | 7,537,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation | 868,000 | 1,039,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Impairment of intangible assets |  | 212,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization | 208,000 | 133,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Share-based compensation expense | 2,722,000 | 3,059,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Deferred income taxes | 426,000 | -310,000 |
| Changes in operating assets and liabilities: | Accounts receivable | -5,145,000 | -1,327,000 |
| Changes in operating assets and liabilities: | Contract assets | -58,000 | -317,000 |
| Changes in operating assets and liabilities: | Inventories | -517,000 | 175,000 |
| Changes in operating assets and liabilities: | Prepaid expenses and other assets | -1,024,000 | -959,000 |
| Changes in operating assets and liabilities: | Income tax receivable, net | -760,000 | -685,000 |
| Changes in operating assets and liabilities: | Accounts payable and accrued liabilities | 652,000 | 1,650,000 |
| Changes in operating assets and liabilities: | Accrued compensation | 992,000 | 1,186,000 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 9,665,000 | 11,393,000 |
| Cash Flows from Investing Activities | Expenditures for property and equipment | -1,252,000 | -262,000 |
| Cash Flows from Investing Activities | Expenditures for finite-life intangible assets | -48,000 | -44,000 |
| Cash Flows from Investing Activities | Net cash used for investing activities | -1,300,000 | -306,000 |
| Cash Flows from Financing Activities | Issuance of common stock upon exercise of options | 965,000 | 398,000 |
| Cash Flows from Financing Activities | Taxes paid on net share settlement of stock awards | -249,000 | -2,278,000 |
| Cash Flows from Financing Activities | Repurchase of common stock | -3,918,000 | -10,000,000 |
| Cash Flows from Financing Activities | Net cash used for financing activities | -3,202,000 | -11,880,000 |
| Cash Flows from Financing Activities | Net increase (decrease) in cash | 5,163,000 | -793,000 |
| Cash and cash equivalents | Beginning of period | 15,287,000 | 16,080,000 |
